NCT04269213 - CPX-351 for the Treatment of Secondary Acute Myeloid Leukemia in Patients Younger Than 60 Years Old | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 29, 2021

Primary Completion Date

January 29, 2027

Study Completion Date

January 29, 2027

Conditions

Acute Myeloid Leukemia Arising From Previous Myelodysplastic SyndromeAcute Myeloid Leukemia With Myelodysplasia-Related ChangesSecondary Acute Myeloid LeukemiaTherapy-Related Acute Myeloid Leukemia

Interventions

DRUG

Liposome-encapsulated Daunorubicin-Cytarabine

Given IV

Trial Locations (4)

13210

RECRUITING

SUNY Upstate Medical Center, Syracuse

14263

RECRUITING

Roswell Park Cancer Institute, Buffalo

15224

RECRUITING

Allegheny Health Network Cancer Institute - West Penn Hospital, Pittsburgh

68198

RECRUITING

University of Nebraska Medical Center, Omaha